Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 study of IMM2510/SYN-2510 + chemotherapy combination in first-line Triple-Negative Breast Cancer in China

Next Previous
Trial Profile

A Phase 1b/2 study of IMM2510/SYN-2510 + chemotherapy combination in first-line Triple-Negative Breast Cancer in China

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 16 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Palverafusp alfa (Primary)
  • Indications Triple negative breast cancer
  • Focus Adverse reactions

Most Recent Events

  • 06 Jan 2026 According to an Instil Bio media release, company has decided to discontinue clinical development of AXN-2510, and that Axion and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. have entered into an agreement to terminate their license and collaboration arrangement for AXN-2510 and AXN-27M.
  • 13 Nov 2024 According to Instil Bio media release, the study targeted to begin in 1H 2025
  • 18 Sep 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top